MCRcI stem cells
Phase 1Biologic
MCRcI stem cells is one of 47 biologic programs targeting Coronary Artery Disease. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
117 competitors in Coronary Artery Disease
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Brilinta
AstraZenecaApproved
Crestor
AstraZenecaApproved
Ozempic
Novo NordiskApproved
Niacor
AbbVieApproved
Effient
CCosette Pharmaceuticals, Inc.
Approved
Glucophage
EMD SeronoApproved
Ranexa
MMenarini International Operations Luxembourg SA
Approved
Cardizem
BBausch Health Americas, Inc.
Approved
Aggrastat
MMedicure
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MCRcI stem cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- HHonya Medical Inc